2016
DOI: 10.1200/jco.2016.34.15_suppl.e23251
|View full text |Cite
|
Sign up to set email alerts
|

A Real-time PCR Assay for the Detection of EGFR Mutations in FFPE Tissue and Plasma Samples of NSCLC Patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…We found that platelets contain a very high amount of wild-type RNA (up to 1.6 million copies of BRAF per sample/680,000 copies BRAF per sample on average), which creates a high non-tumour background even if some tumour-derived exosomes or other tumour-derived RNAweretoadheretoorbetakenupbytheplatelets.Even with the highly sensitive and specific assay applied here, we could not detect any tumour-derived RNA above background in the platelet fraction, despite the assay being able to discriminate allelic frequencies down to 0.01%. Of note, most clinical mutation assays are only specific down to mutant allelic frequencies of >0.1% [26][27][28]. We reviewed theliteratureforthemostappropriate protocol for platelet isolation and applied it across a range of samples in a routine clinical laboratory (ISO 15189).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We found that platelets contain a very high amount of wild-type RNA (up to 1.6 million copies of BRAF per sample/680,000 copies BRAF per sample on average), which creates a high non-tumour background even if some tumour-derived exosomes or other tumour-derived RNAweretoadheretoorbetakenupbytheplatelets.Even with the highly sensitive and specific assay applied here, we could not detect any tumour-derived RNA above background in the platelet fraction, despite the assay being able to discriminate allelic frequencies down to 0.01%. Of note, most clinical mutation assays are only specific down to mutant allelic frequencies of >0.1% [26][27][28]. We reviewed theliteratureforthemostappropriate protocol for platelet isolation and applied it across a range of samples in a routine clinical laboratory (ISO 15189).…”
Section: Discussionmentioning
confidence: 99%
“…Even with the highly sensitive and specific assay applied here, we could not detect any tumour‐derived RNA above background in the platelet fraction, despite the assay being able to discriminate allelic frequencies down to 0.01%. Of note, most clinical mutation assays are only specific down to mutant allelic frequencies of >0.1% [26–28]. We reviewed the literature for the most appropriate protocol for platelet isolation and applied it across a range of samples in a routine clinical laboratory (ISO 15189).…”
Section: Discussionmentioning
confidence: 99%